SCHEMBL2701148

SCHEMBL2701148

[C-]#[N+]c1ccc(NC(=O)C2(C)CC(c3ccc(NC(C)=O)cc3)=NN2)cc1C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.34
BCR P11274 4/20 0.34
MKNK1 Q9BUB5 3/20 0.34
MKNK2 Q9HBH9 3/20 0.34
CYP3A4 P08684 2/20 0.34
CSNK1D P48730 1/20 0.34
PTGS2 P35354 1/20 0.34
HDAC1 Q13547 2/20 0.33
KDR P35968 2/20 0.33
MAP2K1 Q02750 1/20 0.33
TEK Q02763 1/20 0.33
AR P10275 2/20 0.33
MAPT P10636 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PDK2 Q15119 1/20 0.32
KIF11 P52732 1/20 0.32
NISCH Q9Y2I1 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2704154 0.92 HDAC1 (0.37) HDAC1MAPTHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL2701055 0.92 CSNK1D (0.38) CSNK1DHDAC1KDRTEKAR
SCHEMBL2702386 0.90 SMN1; SMN2 (0.36) CYP3A4CSNK1DARMAPTHTT
SCHEMBL2702460 0.90 AR (0.35) ABL1BCRMKNK1MKNK2CYP3A4
SCHEMBL2701360 0.89 HDAC1 (0.36) HDAC1MAPTHSD17B10NISCHHTT
SCHEMBL2704059 0.88 CSNK1D (0.37) ABL1CSNK1DHDAC1KDRTEK
SCHEMBL2702387 0.87 CSNK1D (0.36) ABL1MKNK2CSNK1DHDAC1KDR
SCHEMBL202639 0.86 MAPT (0.46) ABL1BCRKDRTEKMAPT
SCHEMBL2702810 0.86 HSD17B10 (0.35) ABL1BCRMKNK1MKNK2CYP3A4
SCHEMBL2703645 0.85 CSNK1D (0.36) CSNK1DHDAC1KDRARMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088811-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) JANSSEN PHARMACEUTICA N.V. (BE) 2012-01-03 US disclosed
US-20100267670-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) ZHANG XUQING 2010-10-21 US disclosed
US-7781473-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) J & J Pharmaceutical Research & Development, LLC. (US) 2010-08-24 US disclosed
US-20090131365-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) ZHANG XUQING 2009-05-21 US disclosed
US-7465809-B2 Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) JANSSEN PHARMACEUTICA N.V. (BG) 2008-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131365-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AR, NR5A1, NR5A2 ABL1 4194/4885BCR 2164/4885MKNK1 557/4885
US-20100267670-A1 NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AR, NR5A1, NR5A2 ABL1 4194/4885BCR 2164/4885MKNK1 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.